V

Vanda Pharmaceuticals
D

VNDA

4.41500
USD
-0.09
(-1.89%)
مغلق
حجم التداول
43,136
الربح لكل سهم
-1
العائد الربحي
-
P/E
-13
حجم السوق
257,465,334
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    A
    ALKS
    -0.240
    (-0.68%)
    35.260 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    AZN
    AZN
    -0.350
    (-0.47%)
    74.220 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    C
    CRBP
    -0.09000
    (-1.09%)
    8.20000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    J
    JAZZ
    -0.640
    (-0.47%)
    136.050 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    المزيد
الأخبار
المقالات

العنوان: Vanda Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.